Celldex Therapeutics Inc said it agreed to acquire CuraGen Corp for $94.5 million in stock.

With the acquisition, Celldex will add 11 oncology-focused antibodies to its precision targeted immunotherapy platform.

CuraGen is expected to have a cash balance of at least $54.5 million at the close of deal, which is expected to occur in the third quarter.

Celldex will assume $14.1 million of CuraGen's 4 percent convertible debt due in February 2011 at the close of the deal.

CuraGen shares were up 7 percent at $1.34 in pre-market trade, after closing at $1.25 Thursday on Nasdaq.

(Reporting by Jennifer Robin Raj in Bangalore; Editing by Anil D'Silva)